MannKind Expands Executive Leadership Team

Company Announcement - Dominic Marasco, RPh, joins MannKind Corporation as President of the Endocrine Business Unit, effective January 6, 2025 [1] - Mr Marasco reports to Michael Castagna, PharmD, CEO, and is expected to drive strategic growth and operational excellence in the Endocrine Business Unit [2] - Mr Marasco brings over 25 years of experience in the biopharma and biotech sectors, including leadership roles at Envision Pharma Group, BioAgilytix Labs, Syneos Health, Amgen, Sandoz Biopharmaceuticals, and Quintiles Transnational Holdings [2][3] - Mr Marasco began his career as a pharmacist and holds a degree from the Philadelphia College of Pharmacy and completed the Harvard Business School’s Advanced Management Program [4] Company Overview - MannKind Corporation focuses on developing and commercializing innovative inhaled therapeutic products and devices for endocrine and orphan lung diseases [5] - The company aims to address unmet medical needs in diseases such as diabetes, nontuberculous mycobacterial lung disease, pulmonary fibrosis, and pulmonary hypertension [6] - MannKind’s signature technologies include dry-powder formulations and inhalation devices designed for rapid and convenient delivery of medicines to the deep lung [6] - The company’s mission is to empower patients to take control of their health and improve their quality of life [7]